Sorry just saw the fast track query, my take was it would be a pivotal study on prior failures of IO therapy if they went that route. I would need to go back to the preso but it was discussed on the 2/7 or 3/7 chart. They would need more patients to show the impact I believe.
They talked about safety but didn't over stress the point this year. The data point I think I remember was nothing worse than what Keytruda or yervoy saw on its own.
Another disclaimer my memory is rubbish.
VLA Price at posting:
72.0¢ Sentiment: Hold Disclosure: Held
